Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient \[API\]: ketorolac) administered intraoperatively to the tumor resection cavity with standard-of-care (SOC) versus SOC alone in participants with clinical stage II-III triple negative breast cancer (TNBC) undergoing breast-conserving surgery (BCS) who are neoadjuvant therapy naïve.

Participants needed: 400
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: SURGE TherapeuticsUpdated: Jul 23, 2026Locations: 3
Eligibility criteria

Eligible participants will be adults (≥18 years old) who have a history of histo...

Participants will not be eligible if they anticipate requiring the use of a drai...

Read more
Status: Recruiting

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.

Participants needed: 75
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SURGE TherapeuticsUpdated: May 27, 2026Locations: 20
Eligibility criteria

Are aged 18 years or older; [+9]

Have a history of CIS or MIBC; [+4]

Read more
Status: Recruiting

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: SURGE TherapeuticsUpdated: Feb 19, 2026Locations: 4
Eligibility criteria

Males aged 18 years or older at time of informed consent. [+5]

Have an invasive malignancy, other than the disease under study. [+6]

Read more